TYRA
vs
S&P 500
TYRA
S&P 500
Over the past 12 months, TYRA has significantly outperformed S&P 500, delivering a return of +80% compared to the S&P 500's +14% growth.
Stocks Performance
TYRA vs S&P 500
Performance Gap
TYRA vs S&P 500
Performance By Year
TYRA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Tyra Biosciences Inc
Glance View
Tyra Biosciences, Inc. develops therapies for oncology and cancer diseases. The company is headquartered in Carlsbad, California and currently employs 25 full-time employees. The company went IPO on 2021-09-15. The firm is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The firm uses its proprietary SNAP platform, which enables refinement of structural design through iterative molecular SNAPshots. The firm is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR), which are altered in approximately 7% of all cancers. Its lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. In addition, it has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase (RET), and FGFR4-related cancers.